{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:03:39Z","timestamp":1789873419966,"version":"4.0.1"},"reference-count":154,"publisher":"Elsevier BV","issue":"27","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.vaccine.2019.04.092","type":"journal-article","created":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T20:19:46Z","timestamp":1557951586000},"page":"3505-3519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Visceral leishmaniasis: An overview of vaccine adjuvants and their applications"],"prefix":"10.1016","volume":"37","author":[{"given":"Sneha","family":"Ratnapriya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Keerti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amogh A.","family":"Sahasrabuddhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5122-400X","authenticated-orcid":false,"given":"Anuradha","family":"Dube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.04.092_b0005","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrmicro1748","article-title":"Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?","volume":"5","author":"Chappuis","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0010","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1155\/2015\/176545","article-title":"Relapse of visceral leishmaniasis in an HIV-infected patient successfully treated with a combination of miltefosine and amphotericin B","volume":"26","author":"McQuarrie","year":"2015","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0015","first-page":"1","article-title":"decline in clinical efficacy of oral miltefosine in treatment of post kala-azar dermal leishmaniasis (PKDL) in India","volume":"9","author":"Ramesh","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.04.092_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0001657","article-title":"Drug susceptibility in Leishmania isolates following Miltefosine treatment in cases of Visceral Leishmaniasis and post Kala-Azar dermal Leishmaniasis","volume":"6","author":"Bhandari","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.04.092_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2012.00144","article-title":"Adjuvants for Leishmania vaccines: from models to clinical application","volume":"3","author":"Raman","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0030","doi-asserted-by":"crossref","first-page":"12294","DOI":"10.1073\/pnas.1400478111","article-title":"Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants","volume":"111","author":"Maisonneuve","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2019.04.092_b0035","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0264-410X(93)90190-9","article-title":"Adjuvants \u2013 a balance between toxicity and adjuvanticity","volume":"11","author":"Gupta","year":"1993","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.it.2008.09.006","article-title":"New horizons in adjuvants for vaccine development","volume":"30","author":"Reed","year":"2009","journal-title":"Trends Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0045","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2019.04.092_b0050","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.clim.2006.01.017","article-title":"Elevated levels of interferon-\u03b3, interleukin-10, and interleukin-6 during active disease in Indian kala azar","volume":"119","author":"Ansari","year":"2006","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0055","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.it.2007.07.004","article-title":"Interleukin-10 and the pathogenesis of human visceral leishmaniasis","volume":"28","author":"Nylen","year":"2007","journal-title":"Trends Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0060","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/infdis\/jir461","article-title":"IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis","volume":"204","author":"Gautam","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.092_b0065","first-page":"2379","article-title":"IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani","volume":"119","author":"Pitta","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2019.04.092_b0070","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/infdis\/jiu531","article-title":"Interleukin 17A acts synergistically with interferon \u03b3 to promote protection against leishmania infantum infection","volume":"211","author":"Nascimento","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.092_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2012.00251","article-title":"Immunobiology of visceral leishmaniasis","volume":"3","author":"Kumar","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0080","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.4049\/jimmunol.1003588","article-title":"IL-27 and IL-21 are associated with T Cell IL-10 Responses in Human Visceral Leishmaniasis","volume":"186","author":"Ansari","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0085","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.4049\/jimmunol.0802978","article-title":"IL-21 Mediates suppressive effects via its induction of IL-10","volume":"182","author":"Spolski","year":"2009","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2019.04.092_b0090","doi-asserted-by":"crossref","first-page":"e31551","DOI":"10.1371\/journal.pone.0031551","article-title":"Regulatory T cells suppress T cell activation at the pathologic site of human visceral leishmaniasis","volume":"7","author":"Rai","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.04.092_b0095","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12879-014-0653-6","article-title":"Role of CD8+T cells in protection against Leishmania donovani infection in healed Visceral Leishmaniasis individuals","volume":"14","author":"Kaushal","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.092_b0100","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/infdis\/jit401","article-title":"CD8 T cell exhaustion in human visceral leishmaniasis","volume":"209","author":"Gautam","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.092_b0105","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.celrep.2016.05.028","article-title":"Innate immune B cell activation by leishmania donovani exacerbates disease and mediates hypergammaglobulinemia","volume":"15","author":"Silva-Barrios","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2019.04.092_b0110","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1128\/cdli.2.3.291-296.1995","article-title":"Immunoglobulin G subclass-specific antileishmanial antibody responses in Indian kala-azar and post-kala-azar dermal leishmaniasis","volume":"2","author":"Ghosh","year":"1995","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0115","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1128\/JCM.40.3.1037-1043.2002","article-title":"Enzyme-linked immunosorbent assay based on soluble promastigote antigen detects immunoglobulin M (IgM) and IgG antibodies in sera from cases of visceral and cutaneous leishmaniasis","volume":"40","author":"Ryan","year":"2002","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0120","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4103\/0974-777X.62881","article-title":"Leishmaniasis vaccine: where are we today?","volume":"2","author":"Kedzierski","year":"2010","journal-title":"J Glob Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.092_b0125","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0166-6851(94)90057-4","article-title":"Null mutants for the lmcpa cysteine proteinase gene in Leishmania mexicana","volume":"63","author":"Souza","year":"1994","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0130","doi-asserted-by":"crossref","first-page":"18575","DOI":"10.1074\/jbc.M400652200","article-title":"Inactivation of the leishmania tarentolae pterin transporter (BT1) and reductase (PTR1) genes leads to viable parasites with changes in folate metabolism and hypersensitivity to the antifolate methotrexate","volume":"279","author":"El Fadili","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2019.04.092_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0004322","article-title":"Intradermal immunization of leishmania donovani centrin knock-out parasites in combination with salivary protein LJM19 from sand fly vector induces a durable protective immune response in hamsters","volume":"10","author":"Fiuza","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.04.092_b0140","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.vaccine.2008.01.042","article-title":"Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis","volume":"26","author":"Carrillo","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0145","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0264-410X(01)00322-X","article-title":"Immunization with A2 protein results in a mixed Th1\/Th2 and a humoral response which protects mice against Leishmania donovani infections","volume":"20","author":"Ghosh","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0150","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1016\/j.vaccine.2007.08.001","article-title":"Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant","volume":"25","author":"Goto","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0155","doi-asserted-by":"crossref","first-page":"7064","DOI":"10.4049\/jimmunol.165.12.7064","article-title":"Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis","volume":"165","author":"St\u00e4ger","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0160","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1086\/430348","article-title":"A heterologous prime boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis","volume":"191","author":"Tewary","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.092_b0165","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1128\/IAI.00394-07","article-title":"Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+T cells","volume":"75","author":"Coler","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.04.092_b0170","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1016\/j.vaccine.2011.02.096","article-title":"A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis","volume":"29","author":"Chakravarty","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0175","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2015.6","article-title":"From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE","volume":"4","author":"Coler","year":"2015","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41541-017-0025-5","article-title":"A defined subunit vaccine that protects against vector-borne visceral leishmaniasis","volume":"2","author":"Duthie","year":"2017","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2019.04.092_b0185","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00436-005-0008-8","article-title":"Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-\u03b3 production but does not protect BALB\/c mice against Leishmania chagasi intravenous challenge","volume":"98","author":"Marques-Da-Silva","year":"2005","journal-title":"Parasitol Res"},{"key":"10.1016\/j.vaccine.2019.04.092_b0190","doi-asserted-by":"crossref","first-page":"4863","DOI":"10.1016\/j.vaccine.2006.03.005","article-title":"Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani","volume":"24","author":"Gamboa-Le\u00f3n","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0195","doi-asserted-by":"crossref","first-page":"7719","DOI":"10.4049\/jimmunol.0900132","article-title":"Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of leishmania donovani","volume":"183","author":"Sharma","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0200","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1016\/j.vaccine.2005.02.009","article-title":"Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum","volume":"23","author":"Rafati","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0205","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/j.vaccine.2013.02.025","article-title":"Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania","volume":"31","author":"Guha","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0210","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.vaccine.2012.11.068","article-title":"Micro\/nanoparticle adjuvants for antileishmanial vaccines: present and future trends","volume":"31","author":"Badiee","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0215","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0264-410X(00)00401-1","article-title":"Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers","volume":"19","author":"Satti","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0220","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S0031182003003457","article-title":"Prophylactic potential of autoclaved Leishmania donovani with BCG against experimental visceral leishmaniasis","volume":"127","author":"Srivastava","year":"2003","journal-title":"Parasitology"},{"key":"10.1016\/j.vaccine.2019.04.092_b0225","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.vaccine.2007.11.044","article-title":"Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis","volume":"26","author":"Ferreira","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0230","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1365-3083.2008.02171.x","article-title":"Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis","volume":"68","author":"Tripathi","year":"2008","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0235","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.1016\/j.vaccine.2008.08.021","article-title":"Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis","volume":"26","author":"Kumari","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0240","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ijpara.2012.02.013","article-title":"A novel recombinant Leishmania donovani p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis","volume":"42","author":"Gupta","year":"2012","journal-title":"Int J Parasitol"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.092_b0245","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00436-013-3716-5","article-title":"Efficacy of Leishmania donovani trypanothione reductase, identified as a potent Th1 stimulatory protein, for its immunogenicity and prophylactic potential against experimental visceral leishmaniasis","volume":"113","author":"Khare","year":"2014","journal-title":"Parasitol Res"},{"key":"10.1016\/j.vaccine.2019.04.092_b0250","doi-asserted-by":"crossref","first-page":"e86073","DOI":"10.1371\/journal.pone.0086073","article-title":"Characterization of glycolytic enzymes \u2013 rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis","volume":"9","author":"Gupta","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.04.092_b0255","first-page":"1","article-title":"Recombinant NAD-dependent SIR-2 Protein of leishmania donovani: immunobiochemical characterization as a potential vaccine against visceral leishmaniasis","volume":"9","author":"Baharia","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.04.092_b0260","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1017\/S003118201400184X","article-title":"Immunological consequences of stress-related proteins-cytosolic tryparedoxin peroxidase and chaperonin TCP20-identified in splenic amastigotes of Leishmania donovani as Th1 stimulatory, in experimental visceral leishmaniasis","volume":"142","author":"Jaiswal","year":"2015","journal-title":"Parasitology"},{"key":"10.1016\/j.vaccine.2019.04.092_b0265","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/cei.12780","article-title":"Immunoprotective responses of T helper type 1 stimulatory protein-S-adenosyl-L-homocysteine hydrolase against experimental visceral leishmaniasis","volume":"185","author":"Khare","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0270","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1017\/S0031182017001160","article-title":"Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against Leishmania donovani: a step towards exploring novel vaccine candidate","volume":"145","author":"Tandon","year":"2018","journal-title":"Parasitology"},{"key":"10.1016\/j.vaccine.2019.04.092_b0275","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-3083.2007.01939.x","article-title":"Modulatory effect of killed Propionibacterium acnes and its purified soluble polysaccharide on peritoneal exudate cells from C57Bl\/6 mice: Major NKT cell recruitment and increased cytotoxicity","volume":"65","author":"Ananias","year":"2007","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0002729","article-title":"Use of a recombinant cysteine proteinase from leishmania (Leishmania) infantum chagasi for the immunotherapy of canine visceral leishmaniasis","volume":"8","author":"Ferreira","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.04.092_b0285","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2174\/157340711796817913","article-title":"Muramyl dipeptide and its derivatives: peptide adjuvant in immunological disorders and cancer therapy","volume":"7","author":"Ogawa","year":"2011","journal-title":"Curr Bioact Compd"},{"key":"10.1016\/j.vaccine.2019.04.092_b0290","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.vaccine.2004.11.061","article-title":"Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes","volume":"23","author":"Lemesre","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0295","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.vetimm.2008.10.309","article-title":"Effective humoral and cellular immunoprotective responses in Li ESAp-MDP vaccinated protected dogs","volume":"128","author":"Bourdoiseau","year":"2009","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0300","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1016\/j.vaccine.2007.02.083","article-title":"Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: Double-blind randomised efficacy field trial","volume":"25","author":"Lemesre","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0305","doi-asserted-by":"crossref","first-page":"887","DOI":"10.4049\/jimmunol.156.3.887","article-title":"IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response","volume":"156","author":"Bliss","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0310","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.imbio.2012.02.008","article-title":"115kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-\u03b3 induced down-regulation of TNF-\u03b1 mediated MMP-9 activity","volume":"218","author":"Choudhury","year":"2013","journal-title":"Immunobiology"},{"key":"10.1016\/j.vaccine.2019.04.092_b0315","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1016\/j.vaccine.2005.12.039","article-title":"Vaccination with a preparation based on recombinant cysteine peptidases and canine IL-12 does not protect dogs from infection with Leishmania infantum","volume":"24","author":"Poot","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0320","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF01973598","article-title":"Granulocyte-macrophage colony-stimulating factor in combination with pentavalent antimony for the treatment of visceral leishmaniasis","volume":"13","author":"Badar\u00f3","year":"1994","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.092_b0325","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1590\/S1413-86702001000400008","article-title":"Successful use of a defined antigen\/GM-CSF adjuvant vaccine to treat mucosal Leishmaniasis refractory to antimony: A case report","volume":"5","author":"Badaro","year":"2001","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.092_b0330","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/516526","article-title":"Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis","volume":"176","author":"Sundar","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.092_b0335","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.apjtm.2015.06.008","article-title":"Immunogenicity and efficacy of recombinant 78 kDa antigen of Leishmania donovani formulated in various adjuvants against murine visceral leishmaniasis","volume":"8","author":"Nagill","year":"2015","journal-title":"Asian Pac J Trop Med"},{"key":"10.1016\/j.vaccine.2019.04.092_b0340","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00430-014-0367-9","article-title":"Evaluation of the immunogenicity and protective efficacy of Killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis","volume":"204","author":"Thakur","year":"2015","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0345","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.exppara.2008.09.019","article-title":"Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis","volume":"121","author":"Bhardwaj","year":"2009","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0350","doi-asserted-by":"crossref","DOI":"10.1051\/vetres:2005033","article-title":"Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis","author":"Fujiwara","year":"2005","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2019.04.092_b0355","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.1016\/j.vaccine.2005.07.001","article-title":"Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals","volume":"23","author":"Gradoni","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0360","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1016\/j.vaccine.2010.02.089","article-title":"Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE","volume":"28","author":"Trigo","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0365","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1128\/CVI.05024-11","article-title":"KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis","volume":"18","author":"Goto","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0370","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00217","article-title":"A vaccine therapy for canine visceral leishmaniasis promoted significant improvement of clinical and immune status with reduction in parasite burden","volume":"8","author":"Roatt","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0375","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.vaccine.2008.01.026","article-title":"Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime\u00ae) and the recombinant Leish-110f\u00ae + MPL-SE\u00ae vaccine to treat canine visceral leishmaniasis","volume":"26","author":"Miret","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0380","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/pim.12071","article-title":"To investigate the therapeutic potential of immunochemotherapy with cisplatin + 78 kDa + MPL-A against Leishmania donovani in BALB\/c mice","volume":"36","author":"Joshi","year":"2014","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0385","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1017\/S0031182013001959","article-title":"Studies on the protective efficacy of second-generation vaccine along with standard antileishmanial drug in Leishmania donovani infected BALB\/c mice","volume":"141","author":"Joshi","year":"2014","journal-title":"Parasitology"},{"key":"10.1016\/j.vaccine.2019.04.092_b0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0016333","article-title":"Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant","volume":"6","author":"Coler","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.04.092_b0395","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.vaccine.2016.04.067","article-title":"Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis","volume":"34","author":"Duthie","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0400","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1016\/j.vaccine.2004.02.007","article-title":"Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen","volume":"22","author":"Tewary","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0405","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.femsim.2004.05.008","article-title":"Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection","volume":"42","author":"Tewary","year":"2004","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0410","first-page":"6","article-title":"Potency, efficacy and durability of DNA\/DNA, DNA\/protein and protein\/protein based vaccination using gp63 against Leishmania donovani in BALB\/c mice","author":"Mazumder","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.04.092_b0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-3305-7-3","article-title":"Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis","volume":"7","author":"Ramirez","year":"2014","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.vaccine.2019.04.092_b0420","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/eji.200323671","article-title":"Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation","volume":"33","author":"Datta","year":"2003","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0094596","article-title":"Combination of liposomal CpG oligodeoxynucleotide 2006 and miltefosine induces strong cell-mediated immunity during experimental visceral leishmaniasis","volume":"9","author":"Shivahare","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.04.092_b0430","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.vaccine.2009.01.091","article-title":"Advances in saponin-based adjuvants","volume":"27","author":"Sun","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0435","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.vaccine.2003.11.039","article-title":"Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine","volume":"22","author":"Borja-Cabrera","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0440","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0264-410X(02)00444-9","article-title":"Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis","volume":"21","author":"Santos","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0445","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1016\/j.vaccine.2006.02.034","article-title":"Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis","volume":"24","author":"Oliveira-Freitas","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0450","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1016\/j.vaccine.2004.01.072","article-title":"Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapogenins","volume":"22","author":"Palatnik De Sousa","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/S0264-410X(03)00527-9","article-title":"Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine","author":"Santos","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0460","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1016\/S0264-410X(02)00294-3","article-title":"lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S\u00e3o Gon\u00e7alo do Amarante, RN)","volume":"20","author":"Borja-Cabrera","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0465","doi-asserted-by":"crossref","first-page":"6176","DOI":"10.1016\/j.vaccine.2007.06.005","article-title":"Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune\u00aevaccine","volume":"25","author":"Santos","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0470","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1016\/j.vaccine.2008.07.029","article-title":"Immunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil","volume":"26","author":"Borja-Cabrera","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0475","first-page":"7","article-title":"Antigenicity and protective efficacy of a leishmania amastigote-specific protein, member of the super-oxygenase family, against visceral leishmaniasis","author":"Martins","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.04.092_b0480","first-page":"1","article-title":"Antigenicity, immunogenicity and protective efficacy of three proteins expressed in the promastigote and amastigote stages of leishmania infantum against visceral leishmaniasis","volume":"10","author":"Martins","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.04.092_b0485","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.actatropica.2015.11.006","article-title":"A new Leishmania-specific hypothetical protein, LiHyT, used as a vaccine antigen against visceral leishmaniasis","volume":"154","author":"Martins","year":"2016","journal-title":"Acta Trop"},{"key":"10.1016\/j.vaccine.2019.04.092_b0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13071-015-0964-5","article-title":"A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis","volume":"8","author":"Martins","year":"2015","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.vaccine.2019.04.092_b0495","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1017\/S0031182017001731","article-title":"Antigenicity, immunogenicity and protective efficacy of a conserved Leishmania hypothetical protein against visceral leishmaniasis","volume":"145","author":"Dias","year":"2018","journal-title":"Parasitology"},{"key":"10.1016\/j.vaccine.2019.04.092_b0500","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/pim.12287","article-title":"Prophylactic properties of a Leishmania-specific hypothetical protein in a murine model of visceral leishmaniasis","volume":"37","author":"Lage","year":"2015","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0505","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.molimm.2016.06.014","article-title":"A vaccine combining two Leishmania braziliensis proteins offers heterologous protection against Leishmania infantum infection","volume":"76","author":"Duarte","year":"2016","journal-title":"Mol Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0510","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.actatropica.2017.03.008","article-title":"Probing the efficacy of a heterologous Leishmania\/L. Viannia braziliensis recombinant enolase as a candidate vaccine to restrict the development of L. infantum in BALB\/c mice","volume":"171","author":"Santos","year":"2017","journal-title":"Acta Trop"},{"key":"10.1016\/j.vaccine.2019.04.092_b0515","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.molimm.2017.09.017","article-title":"Recombinant small glutamine-rich tetratricopeptide repeat-containing protein of Leishmania infantum: potential vaccine and diagnostic application against visceral leishmaniasis","volume":"91","author":"Dias","year":"2017","journal-title":"Mol Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0520","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1016\/j.vaccine.2008.05.095","article-title":"Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein","volume":"26","author":"Fernandes","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0185438","article-title":"Field trial of efficacy of the Leish-tec\u00ae vaccine against canine leishmaniasis caused by Leishmania infantum in an endemic area with high transmission rates","volume":"12","author":"Grimaldi","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.04.092_b0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0161169","article-title":"Impact of LbSapSal vaccine in canine immunological and parasitological features before and after leishmania chagasi-challenge","volume":"11","author":"Resende","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.04.092_b0535","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-3305-7-61","article-title":"LBSapSal-vaccinated dogs exhibit increased circulating T-lymphocyte subsets (CD4+and CD8+) as well as a reduction of parasitism after challenge with Leishmania infantum plus salivary gland of Lutzomyia longipalpis","volume":"7","author":"Aguiar-Soares","year":"2014","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.vaccine.2019.04.092_b0540","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.vaccine.2007.11.057","article-title":"A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs","volume":"26","author":"Giunchetti","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0545","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/S0264-410X(99)00058-4","article-title":"Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani","volume":"17","author":"Santos","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0550","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1016\/S0264-410X(01)00031-7","article-title":"Vaccination of Balb\/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani","volume":"19","author":"Paraguai de Souza","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0555","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.micinf.2010.06.008","article-title":"Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB\/c mice against Leishmania chagasi and Leishmania amazonensis challenge","volume":"12","author":"Ch\u00e1vez-Fumagalli","year":"2010","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2019.04.092_b0560","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000866","article-title":"Adaptive immunity against leishmania nucleoside hydrolase maps its C-terminal domain as the target of the CD4+ T cell-driven protective response","author":"Nico","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.04.092_b0565","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.provac.2014.07.010","article-title":"Vaccination with nucleoside hydrolase (NH36) of L. (L.) donovani or its C-terminal portion (F3) in formulation with saponin prevents the increase of the proportions of spleen dendritic cells in murine experimental visceral leishmaniasis","volume":"8","author":"Nico","year":"2014","journal-title":"Proc Vaccinol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0570","first-page":"927","author":"Kool","year":"2018","journal-title":"Alum adjuvant: some of the tricks of the oldest adjuvant"},{"key":"10.1016\/j.vaccine.2019.04.092_b0575","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0952-7915(02)00017-1","article-title":"New insights into the mechanism of IL-1\u03b2 maturation","volume":"15","author":"Burns","year":"2003","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0580","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1645\/0022-3395(2000)086[0730:IOPPAL]2.0.CO;2","article-title":"Induction of partial protection against Leishmania donovani by promastigote antigens in negatively charged liposomes","volume":"86","author":"Afrin","year":"2000","journal-title":"J Parasitol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0585","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1128\/IAI.70.12.6697-6706.2002","article-title":"Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB\/c mice","volume":"70","author":"Afrin","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.04.092_b0590","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.vaccine.2005.10.025","article-title":"Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+and CD4+T-cell immune response and protect hamsters against visceral leishmaniasis","volume":"24","author":"Sharma","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0595","doi-asserted-by":"crossref","first-page":"8771","DOI":"10.1016\/j.vaccine.2007.10.028","article-title":"Non-coding pDNA bearing immunostimulatory sequences co-entrapped with leishmanial antigens in cationic liposomes elicits almost complete protection against experimental visceral leishmaniasis in BALB\/c mice","volume":"25","author":"Mazumder","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0600","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/IAI.00611-07","article-title":"Gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB\/c mice infected with Leishmania donovani","volume":"76","author":"Bhowmick","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.04.092_b0605","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1586\/14760584.1.1.111","article-title":"Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines","volume":"1","author":"Aucouturier","year":"2002","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.04.092_b0610","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1016\/j.vaccine.2007.05.010","article-title":"Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis","volume":"25","author":"Moreno","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0615","article-title":"Control of influenza and poliomyelitis with killed virus vaccines","author":"Salk","year":"1977","journal-title":"Science(80\u2013)"},{"key":"10.1016\/j.vaccine.2019.04.092_b0620","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S1674-8301(10)60004-8","article-title":"A review of adjuvants for vaccine candidates","volume":"24","author":"Mutiso","year":"2010","journal-title":"J Biomed Res"},{"key":"10.1016\/j.vaccine.2019.04.092_b0625","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0020-7519(00)00037-0","article-title":"Identification of a 30 kDa antigen from Leishmania (L.) chagasi amastigotes implicated in protective cellular reponses in a murine model","volume":"30","author":"Pinto","year":"2000","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0630","first-page":"2062","volume":"63","author":"Ali","year":"1995","journal-title":"A recombinant leishmania chagasi antigen that stimulates cellular immune responses in infected mice"},{"key":"10.1016\/j.vaccine.2019.04.092_b0635","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0264-410X(00)00207-3","article-title":"Immunization with recombinant LD1 antigens protects against experimental leishmaniasis","volume":"19","author":"Dole","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0640","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.exppara.2011.05.014","article-title":"Efficacy of Leishmania donovani ribosomal P1 gene as DNA vaccine in experimental visceral leishmaniasis","volume":"129","author":"Masih","year":"2011","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0645","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.vaccine.2005.11.011","article-title":"Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis","volume":"24","author":"Rafati","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0650","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.exppara.2007.10.004","article-title":"Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB\/c mice","volume":"118","author":"Rafati","year":"2008","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0655","doi-asserted-by":"crossref","first-page":"e1429","DOI":"10.1371\/journal.pntd.0001429","article-title":"Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection","volume":"5","author":"Mazumder","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.04.092_b0660","doi-asserted-by":"crossref","first-page":"e3091","DOI":"10.1371\/journal.pntd.0003091","article-title":"Combining cationic liposomal delivery with MPL-TDM for cysteine protease cocktail vaccination against leishmania donovani: evidence for antigen synergy and protection","volume":"8","author":"Das","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.04.092_b0665","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1021\/mp2002494","article-title":"Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route","volume":"9","author":"Ravindran","year":"2012","journal-title":"Mol Pharm"},{"key":"10.1016\/j.vaccine.2019.04.092_b0670","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1016\/S0264-410X(01)00058-5","article-title":"Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG","volume":"19","author":"Misra","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0675","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1016\/j.vaccine.2004.03.058","article-title":"Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran","volume":"22","author":"Mohebali","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0680","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1179\/146532806X152890","article-title":"Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major + BCG) in children: an extended phase II study","volume":"26","author":"Khalil","year":"2006","journal-title":"Ann Trop Paediatr"},{"key":"10.1016\/j.vaccine.2019.04.092_b0685","first-page":"351","article-title":"Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major (Alum-ALM) vaccine mixed with BCG plus imiquimod vs. placebo control group","volume":"10","author":"Barati","year":"2015","journal-title":"Iran J Parasitol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0690","doi-asserted-by":"crossref","first-page":"e2853","DOI":"10.1371\/journal.pntd.0002853","article-title":"Clinical and parasitological protection in a leishmania infantum-macaque model vaccinated with adenovirus and the recombinant A2 antigen","volume":"8","author":"Jr Grimaldi","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.04.092_b0695","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0005951","article-title":"Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis","volume":"11","author":"Cec\u00edlio","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.04.092_b0700","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.2147\/IJN.S141069","article-title":"Vaccination with poly(D, L-lactide-co-glycolide) nanoparticles loaded with soluble Leishmania antigens and modified with a TNFalpha-mimicking peptide or monophosphoryl lipid A confers protection against experimental visceral leishmaniasis","volume":"12","author":"Margaroni","year":"2017","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.vaccine.2019.04.092_b0705","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1016\/j.vaccine.2008.08.065","article-title":"Cysteine proteinase type III is protective against Leishmania infantum infection in BALB\/c mice and highly antigenic in visceral leishmaniasis individuals","volume":"26","author":"Khoshgoo","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0710","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1016\/j.vaccine.2010.01.015","article-title":"Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis","volume":"28","author":"Nagill","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.092_b0715","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.parint.2014.10.003","article-title":"Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis","volume":"64","author":"Thakur","year":"2015","journal-title":"Parasitol Int"},{"key":"10.1016\/j.vaccine.2019.04.092_b0720","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.imbio.2015.05.014","article-title":"Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice","volume":"220","author":"Thakur","year":"2015","journal-title":"Immunobiology"},{"key":"10.1016\/j.vaccine.2019.04.092_b0725","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.0141-9838.2004.00711.x","article-title":"Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG + Q mix protects Balb\/c mice from infection","volume":"26","author":"Parody","year":"2004","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0730","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/1471-2180-10-181","article-title":"Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis","volume":"10","author":"Ravindran","year":"2010","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0735","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-3083.2012.02764.x","article-title":"Immunization with leishmania vaccine-alum-BCG and montanide ISA 720 adjuvants induces low-grade type 2 cytokines and high levels of IgG2 subclass antibodies in the vervet monkey (Chlorocebus aethiops) model","volume":"76","author":"Mutiso","year":"2012","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0740","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/erv.12.140","article-title":"The history of MF59 \u00ae adjuvant: a phoenix that arose from the ashes","volume":"12","author":"O\u2019Hagan","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.04.092_b0745","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1517\/14712591003724662","article-title":"MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk","volume":"10","author":"Durando","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2019.04.092_b0750","first-page":"323","article-title":"Adjuvants for pandemic influenza vaccines","volume":"333","author":"Atmar","year":"2009","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0755","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1517\/14712598.2011.573624","article-title":"Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile","volume":"11","author":"Garcon","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2019.04.092_b0760","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/2051013614541440","article-title":"Liposomes as vaccine delivery systems: a review of the recent advances","volume":"2","author":"Schwendener","year":"2014","journal-title":"Ther Adv Vaccines"},{"key":"10.1016\/j.vaccine.2019.04.092_b0765","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2013.12.007","article-title":"Immunomodulatory properties of the vaccine adjuvant alum","volume":"28","author":"Oleszycka","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2019.04.092_b0770","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4110\/in.2015.15.2.51","article-title":"Recent advances of vaccine adjuvants for infectious diseases","volume":"15","author":"Lee","year":"2015","journal-title":"Immune Netw"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19306000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19306000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:32:40Z","timestamp":1759401160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19306000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":154,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0264410X19306000"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.092","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Visceral leishmaniasis: An overview of vaccine adjuvants and their applications","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}